Is this email not displaying correctly? View in your browser.
Send to a colleague
HOME         ABOUT         NEWS         HOT TOPICS         TRIALS         RESOURCES         CONTACT

Latest news from CGRP Forum:
Highlights from the European Academy of Neurology 2021 congress


It really is an exciting time to be in headache,” said CGRP Forum Co-Editor, Professor Peter Goadsby, at this year’s Virtual EAN Congress (19-22 June 2021). Find out which CGRP research he highlighted to the more than 11,000 delegates at the meeting, and catch up on other congress news including latest evidence supporting CGRP and other peptides as potential migraine biomarkers.

Latest anti-CGRP therapy data among congress highlights
Five presentations underlining the safety and efficacy of CGRP MAb and gepant therapies were highlighted by Professor Peter Goadsby, CGRP Forum Co-Editor, during his end-of-conference summary of important migraine data at this year’s EAN.

Read the report »

Questions remain over CGRP as migraine biomarker
CGRP, amylin, VIP and PACAP all have potential as biomarkers for migraine diagnosis, target selection, personalised therapy and clinical trial endpoints, but methodological and other issues have so far prevented clear, consistent indications of which peptide would be most useful.

Read the report »

Multidimensional score may aid access to migraine preventives
A novel composite treatment response score that evaluates significant changes in migraine frequency, headache frequency, severity of migraine attacks and migraine-related disability may aid patient management and expand access to effective preventive treatment.

Read the report »

CGRP MAbs compare well for migraine reduction in patients with multiple treatment failures
In the absence of head-to-head studies, a network meta analysis of placebo-controlled trials of erenumab, fremanezumab and galcanezumab has shown that all three drugs provide comparable efficacy in patients with episodic migraine (EM) or chronic migraine (CM) who experienced multiple treatment failures.

Read the report »

For other recent news from the CGRP Forum, catch up at: News

If you’d like to contribute your experiences of using anti-CGRP therapies or share CGRP research findings, please get in touch.

Becoming a member is easy
Members have free open access simply by registering online.
Join today »
Educational Partners and Supporters (others pending)
You are receiving this email because you have subscribed to receive updates from CGRP Forum.
Should you wish to cancel your subscription, please click here to unsubscribe.